Étude en deux parties, ouverte et randomisée de phase II/III visant à comparer un traitement par dinutuximab et irinotécan avec un traitement par irinotécan seul pour le traitement de deuxième ligne chez des sujets atteints de cancer du poumon à petites cellules résistant ou récidivant.
Distinct / DIV-SCLC-301
NCT03098030
 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
Phase II |
Nicola Raby
514-934-1934 poste 34095
|
(EN) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ADRIATIC
NCT03703297
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Corneille Bashagaluke
514-934-1934 poste 34907
|
(EN) A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients
LAGOON
NCT05153239
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nicola Raby
514-934-1934 poste 34095
|
(EN) A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
20200491
NCT05060016
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Marie-Pierre Brochu
418-525-4444 poste 15768
|
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Josée Allard
418-525-4444 poste 16730
|
(EN) Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Actif en recrutement
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
|
Pierre Bédard
418-835-7121
|
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Patricia Roy
819-346-1110 poste 14082
|
(EN) A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
MK-3475-B98/KEYNOTE-B98
NCT04938817
Actif en recrutement
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
|
Rachelle Dumas
514-345-3511 poste 3378
|
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Actif en recrutement
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
|
Marie-Ève Caron
819-697-3333 poste 63238
|
(EN) Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Pascale Duchesne
418-541-1000 poste 2840
|
Groupe d'étude en oncologie du Québec